KCM
SGMO

KLK Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

KLK Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-44,323
Closed -$57.6K – 47
2023
Q2 		$57.6K Hold
44,323
– – 0.07% 46
2023
Q1 		$78K Hold
44,323
– – 0.1% 46
2022
Q4 		$139K Hold
44,323
– – 0.19% 41
2022
Q3 		$217K Buy
+44,323
New +$228K 0.28% 47
2022
Q1 		$258K Hold
44,323
– – 0.26% 47
2021
Q4 		$332K Hold
44,323
– – 0.32% 42
2021
Q3 		$399K Hold
44,323
– – 0.37% 46
2021
Q2 		$531K Buy
+44,323
New +$502K 0.46% 43

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KLK Capital Management's SGMO Position: Q3 2023 in Review

KLK Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2023, closing a stake of 44,323 shares — an estimated $57.6K sold.

KLK Capital Management first reported a position in SGMO in Q2 2021 and held it in 8 quarters. The position peaked at $531K in Q2 2021. 134 funds tracked by Wall St. Rank hold SGMO as of Q3 2023.

  • KLK Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2023 after selling out during the quarter.
  • KLK Capital Management sold 44,323 SANGAMO THERAPEUTICS INC shares in Q3 2023, an estimated $57.6K.
  • KLK Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2021 and held it in 8 quarters.
  • KLK Capital Management's SANGAMO THERAPEUTICS INC position peaked at $531K in Q2 2021.
  • 134 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2023.

Based on KLK Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.